(ECL) Ecolab - Overview
Stock: Water Treatment, Cleaning Solutions, Pest Elimination
| Risk 5d forecast | |
|---|---|
| Volatility | 18.1% |
| Relative Tail Risk | -6.18% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.54 |
| Alpha | 5.72 |
| Character TTM | |
|---|---|
| Beta | 0.541 |
| Beta Downside | 0.504 |
| Drawdowns 3y | |
|---|---|
| Max DD | 17.26% |
| CAGR/Max DD | 1.40 |
EPS (Earnings per Share)
Revenue
Description: ECL Ecolab January 28, 2026
Ecolab Inc. (NYSE:ECL) is a diversified provider of water, hygiene, and infection-prevention solutions operating through four reportable segments: Global Industrial, Global Institutional & Specialty, Global Healthcare & Life Sciences, and Global Pest Elimination. The company serves a broad customer base-from manufacturing and petrochemicals to foodservice, hospitals, and commercial pest-control-using a mix of direct field sales, corporate account teams, and distributor networks. Founded in 1923 and headquartered in Saint Paul, Minnesota, Ecolab is classified under the Specialty Chemicals sub-industry.
According to the most recent FY 2025 results (released February 2026), Ecolab reported revenue of approximately $15.8 billion, a 3.5 % YoY increase, with an adjusted EBITDA margin of 18.2 % and diluted EPS of $9.73. The Global Industrial segment contributed the largest share of revenue (≈ 45 %), driven by rising demand for water-treatment services in energy-intensive industries amid tighter environmental regulations. The Healthcare & Life Sciences segment posted the strongest growth rate (≈ 7 % YoY), reflecting heightened infection-prevention spending post-COVID-19 and expanding biopharma manufacturing capacity.
Key macro drivers that could affect Ecolab’s outlook include: (1) the global water-treatment market, projected to expand at a 5.1 % CAGR through 2028; (2) US manufacturing PMI trends, which have averaged 52.3 over the past 12 months, indicating modest but stable industrial activity; and (3) regulatory pressure on sanitation standards in food-service and healthcare, which historically correlates with a 0.8 %-1.2 % uplift in segment revenue per 100 basis-point tightening. Investors should monitor the company’s capital-expenditure plans for new digital-monitoring solutions, as these could materially improve recurring revenue visibility.
For a deeper, data-driven assessment of Ecolab’s valuation and risk profile, a quick look at ValueRay’s analyst toolkit can provide useful benchmarks.
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income: 2.08b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA -2.66 > 1.0 |
| NWC/Revenue: 2.62% < 20% (prev 9.35%; Δ -6.73% < -1%) |
| CFO/TA 0.11 > 3% & CFO 2.63b > Net Income 2.08b |
| Net Debt (8.19b) to EBITDA (3.31b): 2.47 < 3 |
| Current Ratio: 1.08 > 1.5 & < 3 |
| Outstanding Shares: last quarter (284.2m) vs 12m ago -0.53% < -2% |
| Gross Margin: 44.48% > 18% (prev 0.43%; Δ 4405 % > 0.5%) |
| Asset Turnover: 68.34% > 50% (prev 70.38%; Δ -2.04% > 0%) |
| Interest Coverage Ratio: 7.29 > 6 (EBITDA TTM 3.31b / Interest Expense TTM 286.8m) |
Altman Z'' 3.20
| A: 0.02 (Total Current Assets 5.96b - Total Current Liabilities 5.53b) / Total Assets 24.70b |
| B: 0.52 (Retained Earnings 12.83b / Total Assets 24.70b) |
| C: 0.09 (EBIT TTM 2.09b / Avg Total Assets 23.53b) |
| D: 0.76 (Book Value of Equity 11.33b / Total Liabilities 14.89b) |
| Altman-Z'' Score: 3.20 = A |
Beneish M -2.98
| DSRI: 1.05 (Receivables 3.25b/3.02b, Revenue 16.08b/15.74b) |
| GMI: 0.98 (GM 44.48% / 43.47%) |
| AQI: 1.06 (AQ_t 0.55 / AQ_t-1 0.53) |
| SGI: 1.02 (Revenue 16.08b / 15.74b) |
| TATA: -0.02 (NI 2.08b - CFO 2.63b) / TA 24.70b) |
| Beneish M-Score: -2.98 (Cap -4..+1) = A |
What is the price of ECL shares?
Over the past week, the price has changed by +3.82%, over one month by +7.72%, over three months by +17.44% and over the past year by +13.53%.
Is ECL a buy, sell or hold?
- StrongBuy: 8
- Buy: 4
- Hold: 13
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the ECL price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 313.1 | 4.7% |
| Analysts Target Price | 313.1 | 4.7% |
| ValueRay Target Price | 345.3 | 15.4% |
ECL Fundamental Data Overview February 12, 2026
P/E Forward = 35.8423
P/S = 5.3537
P/B = 8.7993
P/EG = 3.258
Revenue TTM = 16.08b USD
EBIT TTM = 2.09b USD
EBITDA TTM = 3.31b USD
Long Term Debt = 8.05b USD (from longTermDebt, two quarters ago)
Short Term Debt = 870.4m USD (from shortTermDebt, last quarter)
Debt = 8.83b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 8.19b USD (from netDebt column, last quarter)
Enterprise Value = 94.28b USD (86.09b + Debt 8.83b - CCE 646.2m)
Interest Coverage Ratio = 7.29 (Ebit TTM 2.09b / Interest Expense TTM 286.8m)
EV/FCF = 60.70x (Enterprise Value 94.28b / FCF TTM 1.55b)
FCF Yield = 1.65% (FCF TTM 1.55b / Enterprise Value 94.28b)
FCF Margin = 9.66% (FCF TTM 1.55b / Revenue TTM 16.08b)
Net Margin = 12.91% (Net Income TTM 2.08b / Revenue TTM 16.08b)
Gross Margin = 44.48% ((Revenue TTM 16.08b - Cost of Revenue TTM 8.93b) / Revenue TTM)
Gross Margin QoQ = 44.03% (prev 44.79%)
Tobins Q-Ratio = 3.82 (Enterprise Value 94.28b / Total Assets 24.70b)
Interest Expense / Debt = 0.73% (Interest Expense 64.3m / Debt 8.83b)
Taxrate = 13.89% (91.7m / 660.3m)
NOPAT = 1.80b (EBIT 2.09b * (1 - 13.89%))
Current Ratio = 1.08 (Total Current Assets 5.96b / Total Current Liabilities 5.53b)
Debt / Equity = 0.90 (Debt 8.83b / totalStockholderEquity, last quarter 9.77b)
Debt / EBITDA = 2.47 (Net Debt 8.19b / EBITDA 3.31b)
Debt / FCF = 5.27 (Net Debt 8.19b / FCF TTM 1.55b)
Total Stockholder Equity = 9.42b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.82% (Net Income 2.08b / Total Assets 24.70b)
RoE = 22.03% (Net Income TTM 2.08b / Total Stockholder Equity 9.42b)
RoCE = 11.97% (EBIT 2.09b / Capital Employed (Equity 9.42b + L.T.Debt 8.05b))
RoIC = 10.43% (NOPAT 1.80b / Invested Capital 17.27b)
WACC = 7.23% (E(86.09b)/V(94.93b) * Re(7.91%) + D(8.83b)/V(94.93b) * Rd(0.73%) * (1-Tc(0.14)))
Discount Rate = 7.91% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -0.51%
[DCF Debug] Terminal Value 82.43% ; FCFF base≈1.73b ; Y1≈1.95b ; Y5≈2.60b
Fair Price DCF = 157.8 (EV 52.88b - Net Debt 8.19b = Equity 44.69b / Shares 283.2m; r=7.23% [WACC]; 5y FCF grow 14.34% → 2.90% )
EPS Correlation: 87.44 | EPS CAGR: 28.17% | SUE: 1.34 | # QB: 1
Revenue Correlation: 82.29 | Revenue CAGR: 6.90% | SUE: 0.85 | # QB: 2
EPS next Quarter (2026-03-31): EPS=1.71 | Chg30d=+0.010 | Revisions Net=+1 | Analysts=14
EPS current Year (2026-12-31): EPS=8.53 | Chg30d=+0.042 | Revisions Net=-2 | Growth EPS=+13.2% | Growth Revenue=+7.3%
EPS next Year (2027-12-31): EPS=9.70 | Chg30d=-0.079 | Revisions Net=+0 | Growth EPS=+13.7% | Growth Revenue=+4.9%